ECHS1 as a Lipid Metabolism Biomarker for Pediatric Focal Segmental Glomerulosclerosis
Open Access
- 10 March 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0319049
Abstract
Focal segmental glomerulosclerosis (FSGS) is a common cause of nephrotic syndrome and often leads to end-stage renal disease. However, the underlying pathophysiological mechanisms that contribute to disease progression require further investigation to establish appropriate therapeutic targets and biomarkers. This study aimed to clarify the molecular mechanisms underlying FSGS by focusing on differentially expressed genes (DEGs) and lipid metabolism-related genes (LMRGs). We utilized the GSE69814, GSE129973, and GSE121233 datasets, which comprise glomerular transcriptomes from patients with FSGS, minimal change disease (MCD), and unaffected kidney tissues. We identified 2,459 DEGs from the GSE69814 dataset and 982 DEGs from the GSE129973 dataset. These DEGs intersected 1,450 LMRGs, resulting in 56 differentially expressed LMRGs (DELMRGs). Enrichment analysis revealed that these DELMRGs were primarily involved in fatty acid metabolic processes; localized in microbodies, peroxisomes, and mitochondrial matrices; and exhibited oxidoreductase activity. Protein-protein interaction networks were constructed using Cytoscape, and five hub DELMRGs (enoyl-CoA hydratase, short chain 1 [ECHS1], EHHADH, IDH1, SUCLG1, and ALDH3A2) were identified using multiple algorithms. We assessed the diagnostic performance using receiver operating characteristic curves and expression levels from the GSE121233 dataset, and found that ECHS1 and ALDH3A2 showed strong diagnostic potential. Immunohistochemical verification of clinical specimens from children confirmed significant expression of ECHS1 in FSGS compared with that in normal and MCD tissues. This study highlights ECHS1 as a potential biomarker for pediatric FSGS, suggesting a potential role in early diagnosis or personalized treatment, offering insights into its pathogenesis and paving the way for targeted therapeutic strategies.Keywords
Funding Information
- Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center (Gui Ke AD22035219)
- The Research Project of Guangxi Zhuang Autonomous Region Health Commissiont (Z20240552)
- Natural Science Foundation of Hunan Province (2023JJ30550)
This publication has 55 references indexed in Scilit:
- Targeting Rab7‐Rilp Mediated Microlipophagy Alleviates Lipid Toxicity in Diabetic CardiomyopathyAdvanced Science, 2024
- The key role of altered tubule cell lipid metabolism in kidney disease developmentKidney International, 2024
- Associations Between Cessation of Second-Line Therapies and Relapse Rates of Childhood Refractory Minimal-Change Nephrotic Syndrome: A Single-Center, Retrospective Chart ReviewCurrent Therapeutic Research, 2022
- Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic SyndromeKidney International Reports, 2021
- Bariatric Surgery Is Protective Against Renal Function Decline in Severely Obese Patients in the Long-TermObesity Surgery, 2020
- Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia GravisJAMA Neurology, 2020
- Serine Catabolism Feeds NADH when Respiration Is ImpairedCell Metabolism, 2020
- The Symptoms and Impact of Recurrent Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Conceptual Model of the Patient ExperienceAdvances in Therapy, 2019
- Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosisKidney International, 2018
- Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic SyndromeJAMA Pediatrics, 2018